Evidence map›Paper›PMID 42445496›Full record

ArticleFrontiers in microbiology2026

Diana Angelica Aguilar-Ayala, Marie Sylvianne Rabodoarivelo, Maxime R Eveque-Mourroux, Albin A M Leding, Lindsay Sonnenkalb, Ana Picó Marco, Nicolas Willand, Natalya Serbina, Ulrika S H Simonsson, Ainhoa Lucía and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Diana Angelica Aguilar-AyalaDepartment of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain.
Marie Sylvianne RabodoariveloDepartment of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain.
Maxime R Eveque-MourrouxUniv. Lille, Inserm, Institut Pasteur Lille, U1177 - Drugs and Molecules for living Systems, Lille, France.
Albin A M LedingDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Lindsay SonnenkalbMolecular and Experimental Mycobacteriology, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
Ana Picó MarcoDepartment of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain.
Nicolas WillandUniv. Lille, Inserm, Institut Pasteur Lille, U1177 - Drugs and Molecules for living Systems, Lille, France.
Natalya SerbinaThe Global Alliance for TB Drug Development, New York, NY, United States.
Ulrika S H SimonssonDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Ainhoa LucíaDepartment of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain.
Santiago Ramón-GarcíaDepartment of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The first-in-class diarylquinoline (DARQ) bedaquiline (BDQ) is in the medicines list for drug-resistant tuberculosis. TBAJ-587 is a next-generation DARQ with improved anti- Methods: The Results: The most active compounds, TBAJ-587 and its M3 metabolite, exhibited broth media and concentration dependent efficacy showing a bactericidal effect at ≥5x MIC. Bacterial cultures treated with 1x MIC and 2x MIC of TBAJ-587 resumed growth after 28 days and displayed moderate increased MIC values compared to untreated conditions, which were linked to new variants of BDQ resistance mutations in the Discussion: Unlike commonly performed in

Indexed as

diarylquinolinepharmacokinetics/pharmacodynamicsTBAJ-587time-kill assaytuberculosis

Identifiers

PMID42445496
PMCPMC13357423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.